Gradient Investments’s Precision BioSciences DTIL Stock Holding History

Gradient Investments’s Portfolio DTIL Stock Details DTIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-2	Closed	–	–	1542
2022 Q3	$0	Hold	2	–	–	﹤0.01%	1381
2022 Q2	$0	Buy	+2	New	+$117	﹤0.01%	1250

Other funds holding DTIL

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Gradient Investments's DTIL Position: Q4 2022 in Review

Gradient Investments sold out of Precision BioSciences (DTIL) in Q4 2022, closing a stake of 2 shares.

Gradient Investments first reported a position in DTIL in Q2 2022 and held it in 2 quarters. The position peaked at $0 in Q3 2022. 100 funds tracked by Wall St. Rank hold DTIL as of Q4 2022.

Gradient Investments reported no remaining Precision BioSciences position as of Q4 2022 after selling out during the quarter.
Gradient Investments sold 2 Precision BioSciences shares in Q4 2022.
Gradient Investments first reported a position in Precision BioSciences in Q2 2022 and held it in 2 quarters.
Gradient Investments's Precision BioSciences position peaked at $0 in Q3 2022.
100 funds tracked by Wall St. Rank held Precision BioSciences as of Q4 2022.

Based on Gradient Investments's 13F filing for Q4 2022, filed 10 Jan 2023.